by Truveta Research | Dec 21, 2024 | Research, Research Insights
In an exclusive analysis for the Wall Street Journal, Truveta Research explored mental health-related emergency department visits. The rate of ED encounters related to mental health conditions peaked in 2021 for all conditions studied, besides schizophrenia, which...
by Truveta staff | Dec 19, 2024 | Research
Between the last week of October and the last week of November, there was a 58.8% increase in respiratory virus-associated hospitalizations. For infants and children under the age of 5, respiratory viruses are now associated with 7.9% of hospitalizations in this...
by Truveta Research | Dec 16, 2024 | Research, Research Insights
In partnership with Reuters, Truveta Research explored the percentage of patients who received a first-time diagnosis of type 2 diabetes, cardiovascular disease, or sleep apnea within 15 days of their first-time GLP-1 prescriptions. Truveta Research found that for...
by Truveta Research | Dec 14, 2024 | Research, Research Insights
First-time amphetamine/dextroamphetamine prescription rates remained stable overall, but increased significantly for people 30-44, 45-64, and 65+ years of age. The percentage of prescriptions filled within 5 days of being written reached their lowest values in March...
by Truveta Research | Dec 11, 2024 | Research, Research Insights
The rate of first-time ADHD diagnoses has increased since 2021. The largest increases in first-time ADHD diagnosis rates were seen in the 30-44-year-old and 45-64-year-old age groups. Age groups under 30 years old did not see increases in first-time ADHD diagnosis...
by Truveta staff | Dec 10, 2024 | Data
“For the first time in the history of health, we have enough data at scale to dramatically advance innovation in healthcare” – Michael Slubowski, president & CEO, Trinity Health Electronic health record (EHR) data is rapidly changing how life sciences,...
by Jay Nanduri | Dec 10, 2024 | Technology
In the final article in this series, I will share some thoughts on meeting the following challenge: How to rapidly support new AI scenarios and adjacencies through reuse and transfer learning? Truveta has diverse, multimodal, and up-to-date data on clinical...
by Truveta staff | Dec 6, 2024 | Data
New results released this week from the SURMOUNT-5 clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) are closely aligned to Truveta Research’s GLP-1 comparative effectiveness study, initially shared more than a year ago on November 27, 2023 and...
by Truveta staff | Nov 25, 2024 | Research
RSV-associated hospitalizations increased 191.5% throughout October 2024. RSV-associated hospitalizations also increased in vulnerable populations with a 233.3% in infants and young children (aged 0-4) and 137.0% increase in older adults (65+); 2.4% of all...
by Truveta News | Nov 20, 2024 | News
We are excited to share that our platform Truveta Studio and Truveta Data have earned certified status by HITRUST for information security. This achievement places Truveta in an elite group of organizations worldwide that have earned this certification. HITRUST r2...
